CYBERDYNE Inc. (CYBQY)
OTCMKTS · Delayed Price · Currency is USD
1.220
-0.029 (-2.32%)
At close: Aug 18, 2025
CYBERDYNE Revenue
CYBERDYNE had revenue of 1.00B JPY in the quarter ending June 30, 2025, a decrease of -13.42%. This brings the company's revenue in the last twelve months to 4.23B, down -5.26% year-over-year. In the fiscal year ending March 31, 2025, CYBERDYNE had annual revenue of 4.38B with 0.69% growth.
Revenue (ttm)
4.23B JPY
Revenue Growth
-5.26%
P/S Ratio
9.94
Revenue / Employee
20.04M JPY
Employees
211
Market Cap
291.26M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 4.38B | 30.00M | 0.69% |
Mar 31, 2024 | 4.35B | 1.07B | 32.38% |
Mar 31, 2023 | 3.29B | 1.14B | 52.98% |
Mar 31, 2022 | 2.15B | 275.00M | 14.67% |
Mar 31, 2021 | 1.88B | 83.00M | 4.63% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |